

October 14, 2026

|                                                                                                                                                                                    |                                                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>To</p> <p><b>The Corporate Relations Department</b><br/><b>BSE Limited</b><br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai – 400 001</p> <p><b>Code: 540222</b></p> | <p>To</p> <p><b>The Listing Department</b><br/><b>National Stock Exchange of India Ltd.,</b><br/>Exchange Plaza,<br/>Bandra Kurla Complex, Bandra (E),<br/>Mumbai – 400 051</p> <p><b>Code: LAURUSLABS</b></p> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sub: Update on equity investment in KRKA Pharma Private Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: Our intimation letter dated April 30, 2026**

Dear Sir / Madam,

In continuation to our intimation dated April 30, 2026 with regard to further investment in KRKA Pharma Private Limited (“KRKA”), a joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited (“Company”) and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has invested INR 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) and acquired 107,800,000 (One Hundred Seven Million and Eight Hundred Thousand) equity shares of KRKA at face value of INR 10/- each, aggregating to an amount of INR 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) by way of rights issue.

Consequent to this investment, the total holding of the Company in KRKA is 262,150,000 equity shares of INR 10/- each and the percentage of shareholding by the Company shall remain same at 49%.

Please take the above information on record.

Thanking You,

Yours faithfully,

For **Laurus Labs Limited**

VENKATESWAR  
R REDDY  
GOGIREDDY  
Digitally signed by  
VENKATESWAR REDDY  
GOGIREDDY  
Date: 2026.10.14  
20:00:06 +05'30'

**G. Venkateswar Reddy**

Company Secretary & Compliance Officer

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

CIN : L24239AP2005PLC047518